| pubmed-article:10665753 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10665753 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:10665753 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
| pubmed-article:10665753 | lifeskim:mentions | umls-concept:C0441771 | lld:lifeskim |
| pubmed-article:10665753 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:10665753 | lifeskim:mentions | umls-concept:C0205420 | lld:lifeskim |
| pubmed-article:10665753 | lifeskim:mentions | umls-concept:C0332283 | lld:lifeskim |
| pubmed-article:10665753 | lifeskim:mentions | umls-concept:C1519810 | lld:lifeskim |
| pubmed-article:10665753 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:10665753 | pubmed:dateCreated | 2000-2-15 | lld:pubmed |
| pubmed-article:10665753 | pubmed:abstractText | The favourable experience with the combination regimen of vinorelbine, ifosfamide and cisplatin (NIP) in patients with metastatic non-small cell lung cancer (NSCLC) has led to a protocol assessing this regimen as an induction treatment in patients with stage III unresectable NSCLC, followed by thoracic radiotherapy with concurrent daily cisplatin as a radiosensitizer. Two cycles of NIP were administered 21 days apart; each cycle comprised i.v. vinorelbine 25 mg/m2 on days 1 and 8, i.v. ifosfamide 3 g/m2 on day 1 with MESNA as uroprotection, and i.v. cisplatin 50 mg/m2 on day 1. Radical thoracic radiotherapy commenced on day 43 to a total dose of 64 Gy and i.v. cisplatin 6 mg/m2 was given concurrently prior to each fraction of radiation as a sensitiser. Two more cycles of NIP were given to patients who responded favourably to the induction treatment about 2 weeks after completion of radiation. Between July 1995 and July 1997, 44 patients were treated with this protocol. This treatment schedule was generally well tolerated. Grade 3-4 neutropenia occurred in 50% of the patients and neutropenic sepsis was seen in 8. Grade 3-4 oesophagitis was uncommon. Most of the patients were able to complete the induction and concurrent chemoradiotherapy phase. Major response occurred in 75% of the patients with 2 (4.5%) complete responses (CR). A total of 6 patients achieved CR after chemoradiotherapy. At a median follow-up of 35 months, the median overall survival for all patients was 15 months with a 3-year survival rate of 24%. The median overall survival for stage IIIA patients was 19 months with a 3-year survival rate of 39% in contrast to 13 months' median overall survival and only 15% 3-year survival rate for stage IIIB. The NIP regimen results in a high response rate in NSCLC and this treatment programme seems to benefit selected patients with stage III disease. | lld:pubmed |
| pubmed-article:10665753 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10665753 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10665753 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10665753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10665753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10665753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10665753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10665753 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10665753 | pubmed:issn | 0284-186X | lld:pubmed |
| pubmed-article:10665753 | pubmed:author | pubmed-author:LeeK SKS | lld:pubmed |
| pubmed-article:10665753 | pubmed:author | pubmed-author:LeongS SSS | lld:pubmed |
| pubmed-article:10665753 | pubmed:author | pubmed-author:TanTT | lld:pubmed |
| pubmed-article:10665753 | pubmed:author | pubmed-author:FOXAA | lld:pubmed |
| pubmed-article:10665753 | pubmed:author | pubmed-author:OngY YYY | lld:pubmed |
| pubmed-article:10665753 | pubmed:author | pubmed-author:ChuaE JEJ | lld:pubmed |
| pubmed-article:10665753 | pubmed:author | pubmed-author:HsuAA | lld:pubmed |
| pubmed-article:10665753 | pubmed:author | pubmed-author:AngP TPT | lld:pubmed |
| pubmed-article:10665753 | pubmed:author | pubmed-author:KhooK SKS | lld:pubmed |
| pubmed-article:10665753 | pubmed:author | pubmed-author:WeiFF | lld:pubmed |
| pubmed-article:10665753 | pubmed:author | pubmed-author:WeiV HVH | lld:pubmed |
| pubmed-article:10665753 | pubmed:author | pubmed-author:TanE HEH | lld:pubmed |
| pubmed-article:10665753 | pubmed:author | pubmed-author:FongK WKW | lld:pubmed |
| pubmed-article:10665753 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10665753 | pubmed:volume | 38 | lld:pubmed |
| pubmed-article:10665753 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10665753 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10665753 | pubmed:pagination | 1005-9 | lld:pubmed |
| pubmed-article:10665753 | pubmed:dateRevised | 2009-5-12 | lld:pubmed |
| pubmed-article:10665753 | pubmed:meshHeading | pubmed-meshheading:10665753... | lld:pubmed |
| pubmed-article:10665753 | pubmed:meshHeading | pubmed-meshheading:10665753... | lld:pubmed |
| pubmed-article:10665753 | pubmed:meshHeading | pubmed-meshheading:10665753... | lld:pubmed |
| pubmed-article:10665753 | pubmed:meshHeading | pubmed-meshheading:10665753... | lld:pubmed |
| pubmed-article:10665753 | pubmed:meshHeading | pubmed-meshheading:10665753... | lld:pubmed |
| pubmed-article:10665753 | pubmed:meshHeading | pubmed-meshheading:10665753... | lld:pubmed |
| pubmed-article:10665753 | pubmed:meshHeading | pubmed-meshheading:10665753... | lld:pubmed |
| pubmed-article:10665753 | pubmed:meshHeading | pubmed-meshheading:10665753... | lld:pubmed |
| pubmed-article:10665753 | pubmed:meshHeading | pubmed-meshheading:10665753... | lld:pubmed |
| pubmed-article:10665753 | pubmed:meshHeading | pubmed-meshheading:10665753... | lld:pubmed |
| pubmed-article:10665753 | pubmed:meshHeading | pubmed-meshheading:10665753... | lld:pubmed |
| pubmed-article:10665753 | pubmed:meshHeading | pubmed-meshheading:10665753... | lld:pubmed |
| pubmed-article:10665753 | pubmed:meshHeading | pubmed-meshheading:10665753... | lld:pubmed |
| pubmed-article:10665753 | pubmed:meshHeading | pubmed-meshheading:10665753... | lld:pubmed |
| pubmed-article:10665753 | pubmed:meshHeading | pubmed-meshheading:10665753... | lld:pubmed |
| pubmed-article:10665753 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10665753 | pubmed:articleTitle | Induction chemotherapy followed by concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer. | lld:pubmed |
| pubmed-article:10665753 | pubmed:affiliation | Department of Medical Oncology, National Cancer Centre, Singapore, Singapore. | lld:pubmed |
| pubmed-article:10665753 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10665753 | pubmed:publicationType | Clinical Trial | lld:pubmed |
